Watson C James, Stone Genevra L, Overbeek Daniel L, Chiba Takuyo, Burns Michele M
Harvard Medical Toxicology Program, Boston Children's Hospital, Boston, MA, USA.
Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
J Intern Med. 2022 Feb;291(2):181-196. doi: 10.1111/joim.13431. Epub 2022 Jan 10.
The rules of fair play in sport generally prohibit the use of performance-enhancing drugs (PEDs). The World Anti-Doping Agency (WADA) oversees global antidoping regulations and testing for elite athletes participating in Olympic sports. Efforts to enforce antidoping policies are complicated by the diverse and evolving compounds and strategies employed by athletes to gain a competitive edge. Now between the uniquely proximate 2021 Tokyo and 2022 Beijing Olympic Games, we discuss WADA's efforts to prevent PED use during the modern Olympic Games. Then, we review the major PED classes with a focus on pathophysiology, complexities of antidoping testing, and relevant toxicities. Providers from diverse practice environments are likely to care for patients using PEDs for a variety of reasons and levels of sport; these providers should be aware of common PED classes and their risks.
体育比赛中的公平竞争规则通常禁止使用提高成绩的药物(PEDs)。世界反兴奋剂机构(WADA)负责监督全球反兴奋剂法规,并对参加奥运会项目的精英运动员进行检测。运动员为获得竞争优势而采用的各种不断演变的化合物和策略,使得反兴奋剂政策的执行工作变得复杂。如今,在时间上极为接近的2021年东京奥运会和2022年北京奥运会之间,我们探讨了WADA为防止在现代奥运会期间使用PEDs所做的努力。然后,我们回顾了主要的PED类别,重点关注病理生理学、反兴奋剂检测的复杂性以及相关毒性。来自不同执业环境的医疗服务提供者可能会因各种原因和不同运动水平而照顾使用PEDs的患者;这些医疗服务提供者应该了解常见的PED类别及其风险。